The authors enrolled 976 patients with muscle-invasive bladder cancer to receive neo-adjuvant CMV chemotherapy versus no chemotherapy. Median follow-up was 8 years. Neo-adjuvant therapy resulted in an improved overall survival at 10 years (36% versus 30%). The hazard ratio was 0.84 with a 95% confidence interval of 0.72-0.99 (p=0.037). The authors concluded that neo-adjuvant should be viewed as state-of-the-art compared with cystectomy or radiotherapy alone.
Presented by Richard J. Sylvester, ScD, et al. at the 26th Annual European Association of Urology (EAU) Congress - March 18 - 21, 2011 - Austria Centre Vienna, Vienna, Austria
Reported for UroToday by Christian Doehn, MD, PhD, Department of Urology, University of Lübeck Medical School, Lübeck Germany.
View EAU 2011 Annual Meeting Coverage
